Zacks Research Comments on Clorox's Q3 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX - Free Report) - Equities research analysts at Zacks Research reduced their Q3 2025 earnings estimates for shares of Clorox in a report released on Monday, February 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $1.60 per share for the quarter, down from their previous forecast of $1.68. The consensus estimate for Clorox's current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox's Q4 2025 earnings at $2.14 EPS, FY2025 earnings at $7.15 EPS, Q1 2026 earnings at $1.63 EPS, Q2 2026 earnings at $1.64 EPS, Q3 2026 earnings at $1.66 EPS, FY2026 earnings at $7.12 EPS, Q1 2027 earnings at $1.74 EPS, Q2 2027 earnings at $1.76 EPS and FY2027 earnings at $7.64 EPS.

A number of other equities research analysts have also recently issued reports on CLX. Evercore ISI boosted their price objective on Clorox from $145.00 to $155.00 in a report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price target on Clorox from $171.00 to $173.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. StockNews.com downgraded Clorox from a "buy" rating to a "hold" rating in a report on Sunday, January 5th. DA Davidson lowered their target price on Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. Finally, Wells Fargo & Company lifted their price objective on Clorox from $157.00 to $161.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $158.21.

Clorox Stock Performance

CLX stock traded up $4.34 during trading hours on Wednesday, reaching $157.41. The stock had a trading volume of 1,835,106 shares, compared to its average volume of 1,326,038. Clorox has a fifty-two week low of $127.60 and a fifty-two week high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The stock has a market capitalization of $19.39 billion, a PE ratio of 43.01, a price-to-earnings-growth ratio of 2.58 and a beta of 0.42. The stock has a 50-day simple moving average of $157.87 and a 200 day simple moving average of $159.63.

Clorox (NYSE:CLX - Get Free Report) last issued its quarterly earnings results on Monday, February 3rd. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.39 by $0.16. Clorox had a return on equity of 316.87% and a net margin of 6.38%. During the same quarter in the previous year, the firm earned $2.16 earnings per share.

Institutional Investors Weigh In On Clorox

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Catalyst Capital Advisors LLC purchased a new stake in Clorox in the 3rd quarter valued at $54,000. Los Angeles Capital Management LLC grew its stake in shares of Clorox by 5.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 191,919 shares of the company's stock worth $31,266,000 after acquiring an additional 10,149 shares during the period. Advisors Asset Management Inc. lifted its holdings in Clorox by 43.4% during the third quarter. Advisors Asset Management Inc. now owns 29,865 shares of the company's stock valued at $4,865,000 after purchasing an additional 9,037 shares during the last quarter. Natixis Advisors LLC boosted its position in Clorox by 8.3% during the third quarter. Natixis Advisors LLC now owns 63,476 shares of the company's stock worth $10,341,000 after purchasing an additional 4,839 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Clorox by 1.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 723,906 shares of the company's stock worth $117,932,000 after purchasing an additional 13,038 shares in the last quarter. 78.53% of the stock is owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.